GTG ramps up gene patent litigation efforts
10 July, 2012 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) has cemented its relationship with its intellectual property bulldog, Sheridan Ross, as it seeks to assert its DNA patents in markets outside of the US.
MDI, CSIRO team to cut Penthrox production costs
10 July, 2012 by Dylan Bushell-EmblingThe CSIRO will help MDI improve the production process for homegrown analgesic Penthrox to support the company's EU expansion plans for the product.
Immuron to issue $4.1m worth of options
09 July, 2012 by Dylan Bushell-EmblingImmuron (ASX:IMC) plans to issue $4.1m worth of options exercisable at $0.04 per share - just under twice the current trading price of the company's shares.
Latest AusBiotech journal features special investment edition
05 July, 2012 by AusBiotechAusBiotech is pleased to announce that the July edition of AusBiotech’s journal, Australasian Biotechnology, is now published, featuring a special investment edition.
Cancer Therapeutics proves concept behind new drug
05 July, 2012 by Dylan Bushell-EmblingCancer Therapeutics has revealed positive preclinical results from a trial of CTx-294886 and that it has produced a new small molecule screening platform.
TGA fee hike under fire from industry
05 July, 2012 by Tim DeanSeveral biotech and pharmaceutical industry associations have banded together to call for the recent TGA fee hike to be wound back.
Sirtex sales defy global economic woes
04 July, 2012 by Dylan Bushell-EmblingSirtex Medical (ASX:SRX) recorded strong quarterly and full-year growth for dose sales of its SIR-Spheres targeted radioactive liver cancer treatments.
Starpharma accelerates dendrimer program
04 July, 2012 by Dylan Bushell-EmblingStarpharma (ASX:SPL) is researching expanding its dendrimer nanotechnology platform to a wide range of drug classes besides its initial focus on chemotherapeutics.
QRxPharma may face more trials for MoxDuo
04 July, 2012 by Dylan Bushell-EmblingQRxPharma will meet with the FDA in August to discuss whether more trials of MoxDuo IR are required or existing data reanalysed, but CEO John Holaday is confident its application is “more than adequate for approval”.
AHG, CSIRO team for stem cell research
03 July, 2012 by Dylan Bushell-EmblingAllied Healthcare Group (ASX:AHZ) and the CSIRO have joined forces to develop tissue engineering technologies with the potential to aid tissue repair in the heart.
Registrations now open for the R&D Tax Incentive
03 July, 2012 by AusBiotechThe new financial year has heralded the launch of the application form for the registration of R&D activities under the new R&D Tax Incentive, which opened on 1 July 2012.
CBio to merge with Inverseon
02 July, 2012 by Dylan Bushell-EmblingBrisbane's CBio (ASX:CBZ) plans to merge with US-based Inveseon to create new inflammatory disease focused biotech, Invion.
pSivida enrols first patient for uveitis trial
02 July, 2012 by Dylan Bushell-EmblingpSivida (ASX:PVA) has signed up the first patient for an investigator-sponsored trial of its inserts and ILUVIEN drug in eye disease posterior uveitis.
Phosphagenics enters horse supplement tie-up
02 July, 2012 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) and Equine Nutrition Australia will collaborate to create equine nutritional supplements using the former's TPM technology.
Bioxyne's COPD clinical trial disappoints
29 June, 2012 by Dylan Bushell-EmblingShares in Bioxyne (ASX:BSN) sank 82% on Thursday, after the company revealed a trial of HI 164 OV showed clinical benefit only in COPD patients younger than 65.
